Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3909 - Network Meta-Analysis (NMA) of Treatments for Unresectable Hepatocellular Carcinoma (uHCC)


09 Sep 2017


Poster display session


Hepatobiliary Cancers


Gabriel Tremblay


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


G. Tremblay1, G. Meier2, D. Misurski3, M. Baig3, T. Tamai2, S. Kraljevic4, A. Shor1, A. Forsythe1

Author affiliations

  • 1 Purple Squirrel, Economics, 10010 - New York/US
  • 2 Eisai, Inc, 07677 - WoodCliff Lake/US
  • 3 Eisai, Inc, WoodCliff Lake/US
  • 4 Eisai Co., Ltd, AL10 9SN - Hatfield/GB


Abstract 3909


In a phase 3 randomized controlled study (RCT) lenvatinib (LEN) demonstrated significantly better progression-free survival (PFS) vs sorafenib (SOR) in treatment-naive (1L) uHCC patients. Prior SOR RCTs had been conducted vs placebo (PBO). Our aim was to synthesize all efficacy evidence enabling a comparison of both LEN and SOR to PBO.


EMBASE®, MEDLINE®, MEDLINE® in-process, and Cochrane databases were systematically searched through February 2017 for relevant RCTs in 1L uHCC. Data from the recently completed LEN RCT were added to the review. A conventional NMA based on PFS and overall survival (OS) was performed using a frequentist random effect NMA programmed in R-3.3.1. PBO was used as the reference treatment.


3 Studies met inclusion criteria: 1 recently completed LEN vs SOR study (N = 954) and 2 RCTs comparing SOR to PBO: (1) Llovet 2008 (N = 602) and (2) Cheng 2009 (N = 226). The 3 RCTs were generally comparable with some variability in patient baseline characteristics: mean age, years (63, 66, 61), % male (84, 87, 85), % ECOG score 0-1 (100, 93, 95), % Child–Pugh class A (99, 97, 97), and % prior hepatitis B/C (50/23, 19/28, 73/8) in LEN vs SOR, SOR vs PBO (1), and SOR vs PBO (2), respectively. In the NMA vs PBO, LEN and SOR yielded indirect hazard ratios (HRs) of 0.38 and 0.58 for PFS and 0.63 and 0.69 for OS, respectively. Using LEN as a common comparator, SOR and PBO yielded indirect HRs of 1.52 and 2.63 for PFS and 1.09 and 1.58 for OS, respectively (Table).


This NMA demonstrated that for 1L uHCC patients, both LEN and SOR demonstrated significantly better PFS vs PBO: 62% progression risk reduction for LEN vs 42% for SOR.Table:


InterventionPFS HR (95% CI)OS HR (95% CI)
PBO – Comparator
LEN0.38 (0.30; 0.49)0.63 (0.50; 0.80)
SOR0.58 (0.47; 0.70)0.69 (0.57; 0.83)
LEN – Comparator
SOR1.52 (1.30; 1.76)1.09 (0.94; 1.26)
PBO2.63 (2.06; 3.36)1.58 (1.25; 2.00)

Clinical trial identification


Legal entity responsible for the study

Eisai Inc


Eisai Inc


G. Meier, D. Misurski, M. Baig, T. Tamai: Employee of Eisai Inc. S. Kraljevic: Employee of Eisai Co Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.